Zilganersen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase III for Leukodystrophies. According to GlobalData, Phase III drugs for Leukodystrophies does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Zilganersen sodium LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zilganersen sodium overview
IONIS-GFAPRx (ION-373) is under development for the treatment of Alexander disease (leukodystrophies). The drug candidate acts by targeting glial fibrillary acidic protein (GFAP). It is administered by intrathecal route.
Ionis Pharmaceuticals overview
Ionis Pharmaceuticals (Ionis), formerly ISIS Pharmaceuticals, Inc., focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in California, the US.
For a complete picture of Zilganersen sodium’s drug-specific PTSR and LoA scores, buy the report here.